A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Type of Cancer
Leukemia

Site
Freehold, Howell

Sponsor
Acerta

Protocol Number
ACE-CL-006

To Learn More Call
201-510-0910